旺山旺水通过港交所聆讯 中信证券为独家保荐人

Group 1 - The company, 旺山旺水, has passed the main board listing hearing of the Hong Kong Stock Exchange, with 中信证券 as its sole sponsor [1] - The company possesses nine innovative asset pipelines focusing on three therapeutic areas: neuropsychiatry, reproductive health, and viral infections [1] - Core products include LV232 for the treatment of major depressive disorder and TPN171 for erectile dysfunction [1] Group 2 - The company has achieved commercialization through the sales of dapoxetine, rebapentine, and products like TPN171 and VV116 in Uzbekistan [1] - According to Zhi Shi Consulting, the Chinese antiviral drug market, neuropsychiatric drug market, reproductive health drug market, and antiviral drug market are projected to grow from RMB 103.9 billion, RMB 36.2 billion, and RMB 20.3 billion in 2024 to RMB 123.5 billion, RMB 42.2 billion, and RMB 40.3 billion by 2035, respectively [1]